Clinical trials: Recurrent GBM
Recurrent Central Nervous System Neoplasm
Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme
RATIONALE: Vaccines made from a person's tumor cells and dendritic cells may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00890032
- Testing
- BTSC mRNA-loaded DCs
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- John Sampson
Glioblastoma Multiforme, Glioma, Malignant
Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma
The goal of this clinical trial is to evaluate the safety and efficacy of oncolytic virus TS-2021 in the treatment of recurrent malignant glioma.About 30 eligible participants with recurrent malignant glioma will : Be…
- Trial name
- NCT06585527
- Testing
- TS-2021
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Neurosurgical Institute
Glioblastoma Multiforme, Glioblastoma
Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas.
Relapsed GBMs have a life expectancy of a few months and re-radiation has proven to be safe in terms of toxicity and effective in increasing OS.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioblastoma, Adult
- Trial name
- GLIORAD (NCT04610229)
- Testing
- Hypofractionation guioded by dose painting
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Glioblastoma
Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma
This is a single-center, open-label, dose-range finding Phase I study of hP1A8, a new adjuvant CD200 activation receptor ligand (CD200AR-L), in combination with imiquimod and the GBM6-AD vaccine to treat recurrent glioblastoma…
- Trial name
- NCT04642937
- Testing
- Treatment with hP1A8
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- OX2 Therapeutics
Glioblastoma Multiforme
A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
To evaluate the safety and tolerability of escalating doses of ERAS-801 in study participants with recurrent glioblastoma multiforme (GBM). To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-801.
- Trial name
- NCT05222802
- Testing
- ERAS-801
- Where
- 8 sites in United States
- Volunteers
- 52 people
- Sponsor
- Katmai Pharmaceuticals Inc.
IDH Family Wildtype, Recurrent Anaplastic Astrocytoma
Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
This phase II trial studies how well laser interstitial thermal therapy and lomustine work in treating patients with glioblastoma or anaplastic astrocytoma that has come back.
- Conditions
- IDH Family Wildtype, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma
- Trial name
- NCT03022578
- Testing
- Laser Interstitial Thermal Therapy, Lomustine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC)
Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
The goal of this Phase I clinical trial is to evaluate how the imaging drug 203Pb- RMX-VH-PIB distributes in the body and how much radiation different organs receive in patients with glioblastoma multiforme (GBM) or pancreatic…
- Trial name
- RMX-VH (NCT07733674)
- Testing
- 203Pb-RMX-VHPIB injection, SPECT/CT Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Radiomedix, Inc.
IDH1 wt Allele, Recurrent Anaplastic Astrocytoma
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurrent).
- Conditions
- IDH1 wt Allele, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Gliosarcoma
- Trial name
- NCT03896568
- Testing
- Oncolytic Adenovirus Ad5-DNX-2401, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the…
- Trial name
- NCT03679754
- Testing
- Ad-RTS-hIL-12, veledimex
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alaunos Therapeutics
Recurrent Glioblastoma Multiforme, Recurrent Gliosarcoma
Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme
Primary objective - to determine the 6-month progression free survival (PFS) of adult patients with recurrent glioblastoma multiforme/gliosarcoma treated with bi-weekly temozolomide plus (Avastin) bevacizumab.
- Trial name
- NCT00883298
- Testing
- temozolomide and bevacizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Center for Neurosciences, Tucson
Brain and Central Nervous System Tumors
Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00014105
- Testing
- carboplatin, temozolomide
- Where
- United States
- Sponsor
- Atlantic Health System
Recurrent Glioblastoma Multiforme
Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody.
- Trial name
- NCT00509301
- Testing
- 131-I-chTNT-1/B MAB
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Peregrine Pharmaceuticals
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Glioblastoma, Glioblastoma Multiforme
Study of Pamiparib in Newly Diagnosed and rGBM
This is an open-label, single-center Phase 0/2 study that will enroll up to 30 participants with newly diagnosed (N=12) and recurrent glioblastoma (N=18).
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult
- Trial name
- NCT04614909
- Testing
- Pamiparib, Olaparib, Radiation therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Nader Sanai
Brain and Central Nervous System Tumors
Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas
RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00516607
- Testing
- enzastaurin hydrochloride, temozolomide, pharmacological study
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Glioblastoma, Gliosarcoma
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Primary objective: To estimate 6-month progression free survival probability of pts w recurrent malignant gliomas treated w erlotinib + bevacizumab.
- Trial name
- NCT00671970
- Testing
- Bevacizumab and Erlotinib
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Duke University
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma
This phase I trial studies the side effects and best dose of ascorbic acid when given together with temozolomide in treating patients with high-grade glioma that has come back.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Glioblastoma
- Trial name
- NCT02168270
- Testing
- ascorbic acid, temozolomide, quality-of-life assessment
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Nebraska
Malignant Glioma
Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme
The purpose of this study is to evaluate whether NPC-08 is safety and efficacy in the treatment of newly-diagnosed malignant glioma and recurrent glioblastoma multiforme.
- Trial name
- NCT00919737
- Testing
- NPC-08
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- Nobelpharma
Brain and Central Nervous System Tumors
Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of tipifarnib in treating patients who have recurrent or…
- Trial name
- NCT00005859
- Testing
- tipifarnib
- Where
- 11 sites in United States
- Volunteers
- 136 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
GBM
To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)
This is a multicenter, randomized, controlled study, aiming to evaluate the efficacy and safety of CAN008 administered once-weekly with rRT for treating first tumor recurrence in patients with GBM.
- Trial name
- NCT03746288
- Testing
- CAN008
- Volunteers
- 60 people
- Sponsor
- CANbridge Life Sciences Ltd.